Skip to content

Anxiety: all studies

Page 241 of 769: studies 2,401 to 2,410 of 7,689, newest first. Back to the anxiety overview

Research

The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility

Journal of Psychopharmacology March 1, 2022 Max Wolff, Lea J. Mertens, Marie Walter et al. 57 citations

Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effects and corresponding changes in psychological flexibility. Underlying psychological mechanisms are insufficiently understood. Aim: The purpose of this study was the validation of a psychological model of acceptance/avoidance-promoting psychedelic...

The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review

Journal of Psychoactive Drugs February 28, 2022 Andrew Hodge, Suporn Sukpraprut‐braaten, Matthew R Narlesky et al. 47 citations

There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the "Psychedelic Renaissance." This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain...

Primitivist medicine and capitalist anxieties in ayahuasca tourism Peru

Journal of the Royal Anthropological Institute February 24, 2022 Alex K. Gearin 12 citations

Abstract Analysing healing practices at an ayahuasca tourism centre in Peru, this article illustrates how Shipibo practices of curing and sorcery have adapted to the demands of international clients searching for primitivist healing experiences. At the core of this adaption is the thorny issue of occult power and its relation to capital accumulation. Sorcery here does not serve clients but is...

A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults

Journal of Psychopharmacology February 15, 2022 Jessica L Maples-Keller, Seth D. Norrholm, Mark Burton et al. 53 citations

Background: Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. Aims: This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans. Methods:...

The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)

Journal of Neurochemistry February 12, 2022 Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo et al. 108 citations

Abstract 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) is a naturally occurring tryptamine that primarily acts as an agonist at the 5‐HT1A and 5‐HT2A receptors, whereby affinity for the 5‐HT1A subtype is highest. Subjective effects following 5‐MeO‐DMT administration include distortions in auditory and time perception, amplification of emotional states, and feelings of ego dissolution that...

DOI: 10.1111/jnc.15587 (opens in new tab) Anxiety Agonist Depression economics Pharmacology +1

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Journal of Xenobiotics February 7, 2022 Maurizio Coppola, Francesco Bevione, Raffaella Mondola 29 citations

Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s...

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review

Cureus February 5, 2022 Shawn Ziff, Benjamin Stern, Gregory D. Lewis et al. 32 citations

Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive properties and has been incorporated into religious ceremonies and investigated for its medicinal value. In the mid-20th century, psilocybin, along with most other classic psychedelics (5HT-2A...

Nightmares' Pattern and Predictors among a Saudi University Students during COVID-19 Pandemic.

International Journal of Environmental Research and Public Health February 4, 2022 Amal A Alghamdi, Nora O Alafif, Ahmed S BaHammam et al.

Purpose: During the coronavirus disease 2019 (COVID-19) pandemic quarantine, university students were under various types of stressors, including the exams period, which might have affected their quality and quantity of sleep, and consequently, their quality of life. This study aimed to investigate the pattern and predictors of nightmares among university students and coinvestigate the presence...

Social Support and Psychological Distress among Chronic Pain Patients: The Mediating Role of Mindfulness.

Personality and Individual Differences February 4, 2022 Jenna M Wilson, Carin A Colebaugh, K Mikayla Flowers et al.

Although an inverse relation between social support and psychological distress among chronic pain patients has been previously reported, little is known about what mediates this association. We examined mindfulness as a mediator of the relationship between social support and psychological distress. In this cross-sectional study, chronic pain patients (N=94) completed assessments of social...

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Journal of Psychopharmacology February 1, 2022 Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al. 419 citations

Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods: This...